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ABSTRACT: Protein kinases play a key role in regulating
cellular processes. Kinase dysfunction can lead to disease,
making them an attractive target for drug design. The B-
Raf kinase is a key target for the treatment of melanoma
since a single mutation (V600E) is found in more than
50% of all malignant melanomas. Despite the importance
of B-Raf in melanoma treatment, the molecular mecha-
nism by which the mutation increases kinase activity
remains elusive. Since kinases are tightly regulated by a
conformational transition between an active and inactive
state, which is diﬃcult to capture experimentally, large-
scale enhanced-sampling simulations are performed to
examine the mechanism by which the V600E mutation
enhances the activity of the B-Raf monomer. The results
reveal that the mutation has a twofold eﬀect. First, the
mutation increases the barrier of the active to inactive
transition trapping B-Raf in the active state. The mutation
also increases the ﬂexibility of the activation loop which
might speed-up the rate-limiting step of phosphorylation.
Both eﬀects can be explained by the formation of salt-
bridges with the Glu600 residue.
Kinase proteins play a key role in signaling pathways thatcontrol cellular processes such as cell growth, proliferation,
and diﬀerentiation. Kinases catalyze phosphorylation, the
transfer of a phosphate group from ATP to a substrate protein,
which is necessary for regulating the activity of many enzymes in
the cell, including many kinases themselves. The activity of
kinases is regulated by a tightly controlled transition between an
active state and a catalytically inactive state.
Dysfunction of kinases has been implicated in a number of
diseases, most notably cancer. In many cases, the active−inactive
equilibrium is shifted toward the active state leading to enhanced
signaling and e.g. uncontrolled cell growth. Hence, kinases are
important targets for the development of novel therapeutics to
treat such diseases. One kinase implicated in cancer is B-Raf,
which is part of the RAS-RAF-MEK-ERK signaling pathway.
While there are three isoforms of Raf (A-Raf, B-Raf, and C-Raf),
B-Raf is the most frequently mutated in human cancers. B-Raf is
mutated in 66% of malignant melanomas, and a single point
mutation, V600E, accounts for 80% of these B-Raf mutations.1
(Due to an error in the early sequencing of the BRAF gene, some
report this mutation as V599E.2) The V600E mutation is highly
activating leading to a 500% increase in basal activity compared
to wild-type (WT) B-Raf.3 Thus, the B-Raf V600E mutant
appears to be a promising target for the treatment of melanoma
and currently two inhibitors targeting the mutant have been
approved by the FDA.4 One side eﬀect of these treatments is the
development of secondary tumorigenesis driven by an “inhibitor
paradox”, whereby a drug binding to onemonomer transactivates
a drug-free partner.5 In the cell, WT Raf binds to activated Ras at
the cell membrane where it is activated through dimerization and
phosphorylation. The overactivated RAS will promote dimeriza-
tion of Raf, and binding of an inhibitor to one Raf protomer
transactivates the other.5 Despite B-Raf being an important
target for drug discovery, little is known about the mechanism by
which the V600E mutation activates B-Raf and why the mutant
does not require dimerization to be catalytically active.6 A better
understanding of the eﬀects of this widespread mutation could
open novel pathways in the development of inhibitors to
overcome the paradoxical activation by, e.g., disrupting
interactions which trap the mutant in its active state and/or
favor dimerization.
The kinase family is characterized by a dual-lobe structure
(Figure 1). The smaller N-lobe is made of a β-sheet and an α-
helix (the αC-helix). Two of the β-strands are connected by a
Gly-rich loop (P-loop) which is important for ATP orientation.
The C-lobe is larger andmostly helical with the active site located
in a cleft between the two lobes. The C-lobe contains an
activation loop (A-loop) which has signiﬁcantly diﬀerent
conformations in the active and inactive states. In the active
state, the A-loop is open allowing for ATP and substrate binding
while, in the inactive state, the A-loop is closed blocking the
active site. Another feature of the C-lobe is a short α-helix, known
as the αG-helix.
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Figure 1. Crystal structures of the catalytic domain of B-Raf in the
semiactive, αC-helix out, and DFG-motif out conformations. The
missing loops were added with MODELER.7 The important structural
elements are colored: P-loop (orange), αC-helix (blue), A-loop (red),
αG-helix (yellow). All structures were rendered with VMD.8
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The ﬁrst three residues of the A-loop, DFG, are highly
conserved in kinases. Many kinases adopt a DFG-motif out
inactive structure where the side chain of the Phe residue is
ﬂipped, occupying the ATP-binding site and the Asp points out
of the active site breaking a key salt bridge between Asp594 and
Lys483 (Figure 2a). Another class of inactive structures is
characterized by the αC-helix shifted away from the N-lobe
breaking another key salt bridge formed by Glu501 of the αC-
helix with Lys483.
It has been postulated that the V600E mutation mimics
phosphorylation since the two phosphorylation sites are at
residues 599 and 602,1 but crystal structures have been unable to
conﬁrm this. B-Raf has been crystallized in both inactive
conformations, and in an open structure, typically called the
active state but hereafter called the semiactive state for reasons to
be discussed below. All of these crystal structures have been of
the dimer with inhibitors bound except one.9 While the crystal
structures of WT and mutant B-Raf appear to be very similar,
none of the mutant crystal structures has a fully resolved A-loop,
which is where the V600E mutation is located. Thus, the crystal
structures have been unable to provide a clear understanding of
the eﬀect of the mutation at the atomic level.
As the active−inactive transition is key to the regulation of
kinases, and the crystal structure can only provide snapshots of
the structure, a method examining the dynamics of the kinase is
necessary. Computational approaches have been successfully
applied to examine the eﬀect of cancer-causing point mutations
in several kinases.10−14 The simulations of B-Raf available in the
literature15,16 are much too short to sample the signiﬁcant
conformational changes B-Raf undergoes when transitioning
between the two states. Here we perform much longer MD
simulations and use enhanced sampling methods, including the
longest parallel tempering metadynamics (PT-metaD) sampling
ever performed,17 to reach the time scales on which the
conformational changes take place. PTmetaD has been
successfully applied to study the conformational changes in the
Abl, Src, EGFR, and FGFR kinases.13,14,18,19
The WT semiactive, αC-helix out, and DFG-motif out B-Raf
monomer structures of the kinase domain were taken as the best-
resolved protomer in the dimer pdb structures of 4E26,20
3SKC,21 and 4DBN,22 respectively. The inhibitors in the pdb
structures were removed, and the missing residues of the A-loop
and the mutation were added using MODELLER.7 Following
system setup, the crystal structures were solvated and
equilibrated according to the procedure described in the
Supporting Information (SI). For all simulations, the AM-
BER99sb*-ildn force ﬁeld23 was used for the protein and the
TIP3P model for the waters.24
For each of the six monomer structures, three WT and three
mutant, two 500 ns molecular dynamics (MD) simulations were
performed with the GROMACS 4.6.2 MD engine25 to
characterize the local dynamics of the six structures. Figure S5
shows these six structures colored by RMSF from one trajectory
with the most ﬂexible parts in blue and the least ﬂexible in red.
Comparing the WT structures, the αC-helix out inactive state is
the least ﬂexible. Surprisingly, the DFG-motif out inactive state
appears to be the most ﬂexible, especially in the αC-helix. The
mutation does not have large eﬀects on the ﬂexibility, although it
does explain some of the local diﬀerences. In the active state, the
A-loop of the mutant is slightly less ﬂexible due to the formation
of a salt bridge between the side chains of Glu600 and Arg603
(Figure 2b). This salt-bridge remains formed for the entire
duration of both trajectories in the semiactive state. While the
presence of a Glu600-Arg603 salt-bridge has never been
postulated to our knowledge, it has been suggested that
formation of a salt-bridge between Glu600 and Lys507, the
ﬁnal residue of the αC-helix, has a stabilizing eﬀect.3 Here we ﬁnd
that the Glu600-Lys507 salt-bridge is not stable in one of theMD
trajectories of the semiactive state and only transiently stable in
the second trajectory.
The P-loop of the αC-helix out inactive state is more ﬂexible in
the mutant than the WT due to disruption of hydrophobic
contacts between the N-lobe and A-loop. The Glu600-Arg603
salt-bridge remains intact for the entire length of the simulations,
destabilizing the αC-helix out inactive state.
TheMD results suggest that the V600Emutation stabilizes the
active site and destabilizes the inactive state, agreeing with the
experimental conclusions of Wan et al.,3 but even at 500 ns, MD
simulations are too short to capture signiﬁcant conformational
changes. Thus, we used PT-metaD simulations to characterize
the active to inactive transition and calculate the corresponding
free energy surfaces (FESs). PT-metaD simulations were
performed with the PLUMED 1.3 plugin26 for GROMACS to
capture large scale conformational changes. Thirty-six replicas
over a temperature range of 290−390 K were run for 1.9 μs for a
total of 68.4 μs of sampling with exchanges attempted every 2 ps.
The CVs used here are the distance from a reference state in
terms of contact maps (see SI). Three CVs were used, each one
referenced to one of the three states, the semiactive state (CV1),
the αC-helix out inactive state (CV2), or the DFG-motif out
inactive state (CV3). A similar combination of CVs has been
successfully used together with PTmetaD to converge the
conformational FES associated with the activation of the EGFR
and FGFR kinases13,14 and in many other complex biomolecular
systems.27
The FESs of the WT and mutant B-Raf were constructed from
the replica at 300 K after 1.9 μs of simulation time per replica.
Figure 3 shows the free energy as a function of two of the CVs
used for the PT-metaD. (Please see the SI, Figures S1 and S2, for
a discussion of convergence.) A low value of the distance to the
semiactive state indicates a conformation close to the semiactive
state while a larger value indicates the conformation is far from
the state. WT B-Raf sampled the semiactive state, αC-helix out
inactive state, and a local minimum. The αC-helix out inactive
state is 20 kJ/mol higher in energy than the semiactive state, and
the free energy barrier for the inactive to semiactive transition is
10 kJ/mol while it is 40 kJ/mol for the semiactive to inactive
transition. The energy barrier for the inactive to semiactive
transition of the full enzyme in the cell is likely higher than 10 kJ/
mol since our model only included the kinase domain. In the cell,
Figure 2. Key salt-bridge forming residues in (a) the active site of both
WT and mutant B-Raf and (b) mutant B-Raf only.
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the inactive state is stabilized by interactions between the kinase
domain and its regulatory domains.28
The most striking diﬀerence between the FESs of the WT and
mutant is that the αC-helix out inactive state located at CV2 0.2−
0.3 has a much higher energy in the mutant B-Raf (Figures 3b
and S4), suggesting that the mutant, in contrast to the WT,
spends most of its time in the semiactive state. Indeed, when
unbiased MD simulations of B-Raf V600E are started from the
inactive state, they spontaneously relax to an intermediate
conformation that represents a local free energy minimum
(Figure S3). Also, the basin corresponding to the active state of
the mutant (CV1 0.2−0.4) is much broader than the
corresponding basin for the WT (CV1 0.2−0.3) suggesting
that this state can adopt many more conformations in the mutant
than in theWT. A further diﬀerence is noticed with respect to the
stability of the αG helix as reported below.
To determine representative structures of the minima,
clustering was performed on the 300 K replica to group the
structures based on Cα rmsd. In the WT, the six clusters found in
the semiactive minimum were very similar with respect to the
structure and orientation of the N- and C-lobe. The most
populated cluster is depicted in Figure 3c. The main diﬀerence
between the clusters is in the conformation of the A-loop which is
consistent with the inability to resolve the A-loop in crystal
structures. In most active kinases, the A-loop is extended to allow
access to the active site. Here, as previously reported in the case
of EGFR,13 none of the structures corresponding to the
signiﬁcantly populated clusters had a fully extended A-loop,
and as a result, we refer to these structures as being in a semiactive
state. Recent work by Haling et al. showed that the crystal
structure of B-Raf in complex with its substrate MEK has a fully
extended A-loop29 suggesting that substrate binding and possibly
phosphorylationmay be required for the A-loop to be fully active.
Active state kinases are characterized by other features seen in the
semiactive structures, including the salt-bridges formed between
the Asp of the DFG motif (Asp594) and Lys483 and between
Glu501 in the αC-helix and Lys483 (Figure 2a), residues which
are important for ATP binding in the active site. The active state
also has a β-sheet formed by strands β6 and β9 held together by
three H-bonds. All of the structures have at least two of the H-
bonds formed. Two residues on the catalytic loop, Asp576 and
Lys578, which are involved in coordination of ATP and the
substrate protein in the active site form a salt-bridge in all of the
semiactive structures.
A possible intermediate state for the active−inactive transition
was found in the local minimum at a CV1 value of 0.5 and a CV2
value of 0.45 (Figure 3a,d). The αC-helix is shifted out similar to
the αC-helix out inactive state, and the αG-helix is unfolded.
Partial unfolding of the αG-helix at the transition state was also
seen in a recent PT-metaD study of the EGFR kinase13
suggesting that this unfolding may not be unique to B-Raf.
In the mutant, consistent with the large minimum seen for the
semiactive state in the FES, the clusters correspond to a variety of
structures which have very diﬀerent A-loop conﬁgurations, two
of which are seen in Figure 3e,f. In all ten structures
corresponding to the most populated clusters, the mutated
residue (E600) forms salt-bridges with Arg603 and/or Lys507.
The salt-bridges formed by the E600 increase the stability of the
β6/β9-sheet. The hitherto stabilized β-sheet has a dual eﬀect. It
increases the barrier to the inactive conformation while also
enhancing the ﬂexibility of the A-loop.
The barrier to adopt the inactive conformation is higher
because, in order for the A-loop to fold to its inactive structure,
the β6/β9-sheet needs to break. Another feature of some of the
mutant cluster centers is an unfolded αG-helix, which is
interesting because the intermediate structure identiﬁed for the
WT has an unfolded αG-helix. Figure 4a,b shows the reweighted
FES30 of the rmsd of the αG helix with respect to an ideal α-helix
on the x-axis and CV1 on the y-axis. As the value of the rmsd
increases (and the αG-helix unfolds) the free energy barrier for
the semiactive state is very low in the mutant. Interestingly, one
of the WT clusters that is higher in energy than the semiactive
state also had an unfolded αG-helix but maintains a formed β6/
β9-sheet close to the start of the A-loop.
By lowering the energy penalty to break the hydrophobic
contacts at the end of the A-loop, the salt-bridges formed by
E600 also increase the ﬂexibility of the A-loop, which in turn
leads to a larger ATP binding cavity. The volume of the ATP-
binding site was estimated using mdpocket31 and is plotted as a
function of CV1, the distance from the semiactive state (Figure
Figure 3. FES as a function of distance from semiactive state (x-axis) and
distance from inactive state (y-axis) of theWT (a) andmutant (b) B-Raf.
Structures represent (c) largest cluster in the WT semiactive state and
(d) the possible intermediate structure in the WT active−inactive
transition. For the mutant, (e,f) both structures are from clusters within
the semiactive state.
Figure 4. Reweighted FESs for (a,c) WT and (b,d) mutant B-Raf of the
distance from the semiactive state (x-axis) and the rmsd of the αG-helix
(a,c) or the volume of the ATP-binding site (b,d). The scale represents
the energy relative to the minimum.
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4c,d). This set of FESs was obtained by using the reweighting
technique of Tiwary and Parrinello.30 The great diversity of
semiactive A-loop conformations in the mutant, and a larger
cavity should enhance the ability to release the products of the
phosphorylation. Since the slowest step in the phosphorylation
cycle corresponds in most kinases to product release,32 a more
ﬂexible cavity, having on average a larger volume, could lead to
higher turnover of B-Raf and hence a faster rate of
phosphorylation.
In conclusion, the increased activity of the V600E mutant is
twofold: increased ﬂexibility of the A-loop which likely promotes
the release of the products following phosphorylation of the
substrate and an increased energy barrier between the active and
inactive state. Both are due to salt-bridges formed byGlu600 with
Arg603 and Lys507. While the importance of the Glu600-Lys507
salt-bridge has been recognized, the formation of the Glu600-
Arg603 salt-bridge as a stabilizing element has not been
promoted. Disrupting the formation of the Glu600-Arg603
salt-bridge could be a viable pathway for inhibitor development.
A possible intermediate in the active to inactive transition of WT
B-Raf has also been identiﬁed. An inhibitor that targets this state
may be a viable option for cancers with Ras mutations. The
intermediate and minimum energy structures have also revealed
the importance of the αG-helix in the conformational changes in
B-Raf, which may be applicable to other kinases. Since WT and
mutant B-Raf have very similar backbone structures and the
resolution of the A-loop in crystal structures is very poor, our
simulations have revealed new insight into the structure and
dynamics of the B-Raf kinase.
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